EGFR and hepatocellular carcinoma: The combination of YTHDF1 silencing and EGFR inhibition dramatically inhibited HCC tumor metastasis after inadequate radiofrequency ablation in vivo, suggesting YTHDF1 as a potential therapeutic target for metastatic HCC.